Pharmacological treatment for chronic obstructive pulmonary disease (COPD) aims to
alleviate symptoms and reduce the future risk of events such as exacerbations, disease …

Introduction Chronic obstructive pulmonary disease (COPD) is one of the main causes of
death and disability worldwide. Many treatment options are now available, but criteria for …

Triple inhaled therapy for chronic obstructive pulmonary disease (COPD) consists of an
inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA) and a long-acting muscarinic …

Precision medicine is a patient-specific approach that integrates all relevant clinical, genetic
and biological information in order to optimise the therapeutic benefit relative to the …

Background Previous studies have highlighted a relationship between reduction in rate of
exacerbations with therapies containing inhaled corticosteroids (ICS) and baseline blood …

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality
worldwide; many recent advances have been made in many aspects of the disease. The aim …

Introduction There is an interest in the role of blood eosinophils for predicting inhaled
corticosteroid (ICS) response in chronic obstructive pulmonary disease (COPD). Most data …

Identification of a biomarker that predicts response to inhaled corticosteroids (ICS) would
help evaluate the risk/benefit profile of ICS in chronic obstructive pulmonary disease (COPD) …

Background Chronic obstructive pulmonary disease (COPD) is characterised by progressive
airflow limitation and chronic inflammation. Predicting exacerbations of COPD, which …

Abstract The Spanish COPD Guidelines (GesEPOC) were first published in 2012, and since
then have undergone a series of updates incorporating new evidence on the diagnosis and …